University of Alberta

Helmholtz Center for Infection Research

Gesellschaft Fuer Biotechnologische Forschung Mbh (gbf)

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Carlos A Guzman

Michael Houghton

Abdolamir Landi

Michael Logan

Darren Hockman

John L Law

Thomas Ebensen

Siegfried Weiss

Kenneth Nigel Timmis

Ayub Darji

Birgit Gerstel

Trinad Chakraborty

Petra Wachholz

Jürgen Wehland

Michael Morr

Götz Milkereit

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

Hepatitis C virus immunogenic compositions and methods of use thereof

The present invention is directed to an attenuatedcomprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuatedcomprising the eukaryotic expression vector.

[object Object]

Growing community of inventors

Braunschweig, Germany

Carlos A Guzman